1 October 2021 - The October 2021 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The October issue of the Schedule includes a few new/revised listings:

• Brolucizumab (Beovu) - new medicine
• Cyclosporin (Ikervis) - new indication
• Ofatumumab acetate (Kesimpta) - new medicine
• Pomalidomide (Pomalyst) - new indication
• Teriparatide (Terrosa) - new biosmilar medicine
• Upadacitinib monohydate (Rinvoq) - new indications
• Ustekinumab (Stelara) - new indication

Read Summary of Changes